Terapevt Arkh
-
Multicenter Study Observational Study
[Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study].
Evaluation of the practice of using trimebutine (tablets, 300 mg, extended release), for the treatment of patients with functional gastrointestinal disorders (FGID) in primary health care. ⋯ The present prospective observational multicenter non-interventional study has demonstrated that trimebutine is an effective approach to treating FGID.
-
Randomized Controlled Trial Multicenter Study
[The use of drug based on technologically processed antibodies to endocannabinoid receptor type 1 in the treatment of obesity in adults: results of a multicenter double blind placebo controlled randomized clinical trial].
To evaluate the clinical efficacy and safety of Dietressa at a dose of 6 tablets per day for 24 weeks in the treatment of patients with Class 1 obesity. To compare the clinical efficacy of two treatment regimens (1 tablet 6 times per day and 2 tablets 3 times per day) for 24 weeks in the treatment of patients with Class 1 obesity. ⋯ The monotherapy with Dietressa is safe, and it leads to at least 5 percent reduction in body weight during 24 weeks of therapy in patients with Class 1 obesity.